QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ryan, G. J Articles by Cook, C. B Search for Related Content PubMed PubMed Citation Articles by Ryan, G. J Articles by Cook, C. B

AMBULATORY CARE

Chromium as Adjunctive Treatment for Type 2 Diabetes

Clinical Assistant Professor, Department of Clinical and Administrative Sciences, Southern School of Pharmacy, Mercer University, Atlanta, GA

Nancy S Wanko, MS RD LD

Clinical Dietitian, Department of Nutrition Services, Grady Health System, Atlanta

Andrea R Redman, PharmD BCPS

Clinical Assistant Professor, Department of Clinical and Administrative Sciences, Southern School of Pharmacy, Mercer University

Curtiss B Cook, MD

Associate Professor, Department of Endocrinology and Metabolism, School of Medicine, Emory University, Atlanta

Reprints: Gina J Ryan PharmD BCPS CDE, Department of Clinical and Administrative Sciences, Southern School of Pharmacy, Mercer University, 3001 Mercer University Dr., Atlanta, GA 30341-4155, FAX 678/547-6384, E-mail ryan_gj{at}mercer.edu

OBJECTIVE: To review the chemistry, pharmacology, efficacy, and safety of trivalent chromium in the treatment of type 2 diabetes and hyperlipidemia.

DATA SOURCES: The English literature was searched from 1966 through May 2002 using MEDLINE, International Pharmaceutical Abstracts, and EMBASE. The key words included chromium, glucose, lipids, and diabetes. Pertinent references from review articles and studies were used as additional sources.

DATA SYNTHESIS: Trivalent chromium is an essential nutrient and has a key role in lipid and glucose metabolism. Supplementation with chromium does not appear to reduce glucose levels in euglycemia. It may, however, have some efficacy in reducing glucose levels in hyperglycemia. The effects of chromium on lipid levels are variable. Chromium in doses <1000 µg/d appears to be safe for short-term administration. Kidney function and dermatologic changes need to be monitored.

CONCLUSIONS: Chromium appears to be a safe supplement and may have a role as adjunctive therapy for treatment of type 2 diabetes. Additional large-scale, long-term, randomized, double-blind studies examining the effect of various doses and forms of chromium are needed.

Key Words: chromium, diabetes, glucose, lipids

This article has been cited by other articles:

				American Diabetes Association Nutrition Recommendations and Interventions for Diabetes: A position statement of the American Diabetes Association Diabetes Care, January 1, 2008; 31(Supplement_1): S61 - S78. [Full Text] [PDF]

				American Diabetes Association Nutrition Recommendations and Interventions for Diabetes: A position statement of the American Diabetes Association Diabetes Care, January 1, 2007; 30(suppl_1): S48 - S65. [Full Text] [PDF]

				C. Rink, S. Roy, S. Khanna, T. Rink, D. Bagchi, and C. K. Sen Transcriptome of the subcutaneous adipose tissue in response to oral supplementation of type 2 Leprdb obese diabetic mice with niacin-bound chromium Physiol Genomics, November 21, 2006; 27(3): 370 - 379. [Abstract] [Full Text] [PDF]

				American Diabetes Association Nutrition Recommendations and Interventions for Diabetes-2006: A position statement of the American Diabetes Association. Diabetes Care, September 1, 2006; 29(9): 2140 - 2157. [Full Text] [PDF]

				American Diabetes Association Standards of Medical Care in Diabetes-2006 Diabetes Care, January 1, 2006; 29(suppl_1): S4 - S42. [Full Text] [PDF]